Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023)
Pulse Biosciences (PLSE) posted quarterly Non-Current Debt of $65.0 million for Q1 2023, little changed quarter-over-quarter from $65.0 million in Q4 2022.
Pulse Biosciences (PLSE) Non-Current Debt (2021 - 2023) Analysis & Trends
Pulse Biosciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $65.0 million for Q1 2023.
- In Q1 2023, Non-Current Debt changed N/A year-over-year to $65.0 million; the TTM figure through Mar 2023 stood at $65.0 million (changed N/A YoY), while the FY2022 annual figure was $65.0 million, changed N/A from the prior year.
- Non-Current Debt for Q1 2023 stood at $65.0 million, roughly flat from $65.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $65.0 million in Q3 2022, with the low at $41.0 million in Q1 2021.
- The 3-year median for Non-Current Debt is $65.0 million (2022), against an average of $59.0 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 13.51 Bn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 4.15 Bn |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 399.42 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | 12.55 Bn |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 202.90 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 4.57 Bn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | 1.86 Bn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 8.62 Bn |
| 10 | Pulse Biosciences | 3.33 Bn | 3.33 Bn | 161,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 65.00 Mn |
| Dec 31, 2022 | 65.00 Mn |
| Sep 30, 2022 | 65.00 Mn |
| Mar 31, 2021 | 41.00 Mn |